GleamWall
中文EN

PVLA PALVELLA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$10.82M$12.47M$9.33M$7.12M$6.53M$5.12M$4.07M$2.54M
SG&A expense$11.90M$8.93M$5.52M$4.18M$3.65M$4.13M$3.80M-$5.20M
Operating income-$22.73M-$21.41M-$14.86M-$11.30M-$10.18M-$9.25M-$7.87M-$1.48M
Interest expense———$0$0$0—$181,000
Pretax income-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$3.95M
Income tax$0$0$0$0$0$0$0$0
Net income-$24.64M-$21.87M-$15.77M-$12.71M-$11.35M-$9.47M-$8.19M-$6.07M
EPS (basic)-1.70-1.52-1.20—-1.03-0.86-0.74—
EPS (diluted)-1.70-1.52-1.20—-1.03-0.86-0.74—
Weighted avg. shares (diluted)14.53M14.36M13.09M—11.06M11.05M11.01M—
Banking
Net interest income$2.55M$1.97M$1.07M$520,000$628,000$690,000$752,000$281,000
Balance sheet
Cash & equivalents$193.30M$187.80M$206.39M$57.98M$63.57M$70.43M$75.63M$83.60M
Short-term investments$43.38M$62.78M$55.46M$0————
Receivables———$0$0$0$0$358,000
Current assets$238.97M$253.03M$263.23M$58.99M$66.94M$73.75M$79.44M$88.23M
Total assets$239.40M$253.51M$263.76M$59.56M$66.94M$73.75M$79.44M$88.23M
Current liabilities$14.93M$11.95M$9.12M$11.34M$10.31M$9.62M$8.98M$12.04M
Total liabilities$41.48M$36.64M$31.45M$31.58M$28.25M$25.97M$23.86M$25.63M
Shareholders' equity$197.92M$216.87M$232.31M$27.98M$38.68M$47.78M$55.58M$62.61M
Shares outstanding14.61M14.40M14.31M12.38M11.09M11.06M11.02M11.01M
Cash flow statement
Operating cash flow-$14.43M-$12.85M-$10.86M-$4.93M-$7.88M-$5.43M-$6.77M-$2.51M
Investing cash flow$19.57M-$7.03M-$55.44M—$0$0$0—
Financing cash flow$452,000$1.28M$214.73M-$49,000$242,000$349,000-$1.20M$87.09M
Stock-based compensation$5.42M$5.16M$3.38M$2.08M$1.79M$1.43M$1.09M-$393,000

Free plan shows the latest 8 periods; Pro shows all 53 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.